Cytotoxic ribonuclease variants
This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.
1. A method for producing a modified cytotoxic ribonuclease, comprising:
a) producing a cytotoxic ribonuclease from cells transformed with an expression vector encoding a modified cytotoxic ribonuclease; and
b) purifying said modified cytotoxic ribonuclease;
wherein said modified cytotoxic ribonuclease comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:1 solely by four to seven amino acid substitutions, wherein said four to seven amino acid substitutions are located at positions of SEQ ID NO:1 selected from the group consisting of 7, 31, 38, 39, 67 and 85-94, wherein at least one of the four to seven amino acid substitutions is at a position corresponding to any one of positions 85-94 of SEQ ID NO: 1, wherein at least three of the four to seven amino acid substitutions are at positions corresponding to positions 7, 31, 38, 39, or 67 of SEQ ID NO:1.
2. The method of claim 1 , wherein said cells are E. coli cells.
3. The method of claim 2 , wherein said purifying comprises treating inclusion bodies from E. coli with a buffer solution until dissolved thoroughly.
4. The method of claim 1 , wherein said purifying comprises dialyzing said modified cytotoxic ribonuclease against PBS buffer.
5. The method of claim 4 , further comprising the step of filtering the dialyzed modified cytotoxic ribonuclease.
6. The method of claim 1 , further comprising the step of determining protein concentration of the purified modified cytotoxic ribonuclease.
7. A method for producing a modified cytotoxic ribonuclease, comprising:
a) producing a cytotoxic ribonuclease from cells transformed with an expression vector encoding a modified cytotoxic ribonuclease; and
b) purifying said modified cytotoxic ribonuclease;
wherein said modified cytotoxic ribonuclease comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO: 1 solely by three or more amino acid substitutions at positions corresponding to positions of SEQ ID NO:1 selected from the group consisting of 38, 39, 67 and 85-94, wherein at least one of the three or more amino acid substitutions is at a position corresponding to any one of positions 85-94 of SEQ ID NO:1, wherein at least two of the three or more amino acid substitutions are at positions corresponding to positions 38, 39 or 67 of SEQ ID NO:1.
8. The method of claim 7 , wherein said cells are E. coli cells.
9. The method of claim 8 , wherein said purifying comprises treating inclusion bodies from E. coli with a buffer solution until dissolved thoroughly.
10. The method of claim 7 , wherein said purifying comprises dialyzing said modified cytotoxic ribonuclease against PBS buffer.
11. The method of claim 10 , further comprising the step of filtering the dialyzed modified cytotoxic ribonuclease.
12. The method of claim 7 , further comprising the step of determining protein concentration of the purified modified cytotoxic ribonuclease.
13. A method for producing a modified cytotoxic ribonuclease, comprising:
a) producing a cytotoxic ribonuclease from cells transformed with an expression vector encoding a modified cytotoxic ribonuclease; and
b) purifying said modified cytotoxic ribonuclease;
wherein said modified cytotoxic ribonuclease comprises an amino acid sequence which differs from the amino acid sequence of SEQ ID NO:1 solely by two or more modifications at positions corresponding to positions of SEQ ID NO:1 selected from the group consisting of 38, 39, 67 and 85-94, wherein at least one of the two or more modifications is an amino acid substitution at a position corresponding to any one of positions 85-94 of SEQ ID NO:1, and wherein at least one of the two or more modifications is selected from the group consisting of: (i) a substitution at a position corresponding to position 39 of SEQ ID NO: 1, (ii) a substitution at a position corresponding to position 67 of SEQ ID NO: 1, (iii) substitutions at positions corresponding to positions 38 and 39 of SEQ ID NO: 1, and (iv) substitutions at positions corresponding to positions 38, 39 and 67 of SEQ ID NO: 1.
14. The method of claim 13 , wherein said cells are E. coli cells.
15. The method of claim 14 , wherein said purifying comprises treating inclusion bodies from E. coli with a buffer solution until dissolved thoroughly.
16. The method of claim 13 , wherein said purifying comprises dialyzing said modified cytotoxic ribonuclease against PBS buffer.
17. The method of claim 16 , further comprising the step of filtering the dialyzed modified cytotoxic ribonuclease.
18. The method of claim 13 , further comprising the step of determining protein concentration of the purified modified cytotoxic ribonuclease.